Alzheimer’s Disease More Common in Seniors, New Study Reveals
A groundbreaking study has unveiled that the prevalence of Alzheimer’s disease among individuals over 85 years old is significantly higher than previously estimated. The findings are particularly concerning as they highlight the impact of Alzheimer’s in older populations and suggest a possible method for earlier diagnosis through a simple blood test.
The Study and Its Findings
Conducted by researchers from King’s College London, the University of Gothenburg, and Stavanger University Hospital, the study examined 11,486 blood samples from individuals aged 57 and older participating in the Trondelag Health Study in Norway. The primary focus was on identifying biomarkers linked to the onset of dementia.
Results indicate that over 10% of people aged 70 and above might qualify for available treatments aimed at slowing early stages of Alzheimer’s. Notably, the research revealed a staggering increase in Alzheimer’s disease neuropathological changes (ADNC)—protein deposits in the brain associated with nerve cell death—rising from just under 8% in those aged 65-69 to over 65% in individuals exceeding 90 years of age.
Symptoms and Eligibility for Treatment
The study also found that among the over-70 age demographic, approximately 10% were living with symptomless pre-clinical Alzheimer’s disease, while nearly 10% exhibited signs of Alzheimer’s dementia. About 10.4% were in the prodromal stage—where cognitive issues are noticeable but not classified as full-blown dementia.
Researchers estimate that 11% of individuals aged 70 and older may be suitable for antibody treatments, which can help slow down disease progression. Currently, drugs like lecanemab and donanemab have been approved for use in the UK but are not available through the NHS due to concerns over their cost-effectiveness.
Importance of Early Diagnosis
Dr. Richard Oakley, Associate Director of Research and Innovation at Alzheimer’s Society, emphasized the significance of these findings. He commented on the study’s scale, noting that it serves as a sobering reminder of the growing dementia crisis in the UK. Alzheimer’s is currently the leading cause of death in the country, and the new data suggests its true impact may be even greater than previously thought.
The researchers believe that blood tests could revolutionize the diagnosis of Alzheimer’s. These tests offer a more expedient, affordable alternative compared to traditional diagnostic methods, such as lumbar punctures or PET scans. A forthcoming trial is set to evaluate the effectiveness of blood tests in memory clinics, with results expected within three years.
Background
The increasing prevalence of Alzheimer’s has raised alarms globally, particularly as populations age. Understanding the disease’s onset and progression has become crucial for managing its impact on individuals and healthcare systems alike. As dementia cases rise, the importance of developing reliable and accessible diagnostic methods cannot be overstated.
The findings from this extensive study may provide critical insights for further research and understanding the dynamics of Alzheimer’s disease, potentially aiding in the early detection and better management of the condition.
Source: Original Article
